The public record places dihexa at the preclinical stage and nowhere further. It is an orally active angiotensin IV analog described by Washington State University researchers in the early 2010s, proposed to work by amplifying hepatocyte growth factor signaling at the c-Met receptor, with an evidence base confined to cell-based assays and rodent studies. No approval pathway is publicly underway, and part of the founding literature has since been withdrawn.
Dihexa's public record ends at cell-based and rodent studies, with no registered human trial, no disclosed sponsor program, and a 2025 retraction of the paper tying its cognitive effects to hepatocyte growth factor and c-Met signaling.
Much of what circulates online reads dihexa as a drug in development. The published record does not support that reading: it holds laboratory and animal work, with no completed trial naming the compound as the investigational agent in registries such as ClinicalTrials.gov. The distinction is not cosmetic, since a research-stage compound exists in publications while an investigational drug has a sponsor, a protocol, regulatory oversight, and adverse-event reporting behind it.
The peer-reviewed record for dihexa spans cell assays and rodent behavioral studies from roughly 2012 onward and contains no published human pharmacokinetic, tolerability, or efficacy data.
Two institutions carry most of this history, and the pattern is the ordinary one in academic drug discovery. Patent rights sat with a university, which cannot itself run a toxicology program or file an investigational new drug application, so the chemistry moved to a startup under license. That chain matters practically: a molecule with no identifiable, funded sponsor has no one positioned to run the studies approval would require.
The angiotensin IV analog chemistry was assigned to Washington State University and licensed to M3 Biotechnology, which was renamed Athira Pharma in 2019 and carried fosgonimeton, not dihexa, into human trials.
Companies almost never publish a post-mortem explaining why one candidate was set aside for another, so an honest account separates the documented from the inferred. What is documented is the outcome: the licensee took a different hepatocyte growth factor and MET positive modulator into humans, and that compound later missed its primary endpoint. What is inference is the reason, since candidates are routinely dropped for unpublished causes such as nonlinear exposure, a difficult metabolite, costly manufacturing at scale, or a toxicology finding.
| Criteria | Dihexa | Fosgonimeton (ATH-1017) |
|---|---|---|
| Route | Oral | Subcutaneous injection |
| Furthest stage reached | Preclinical | Phase 2/3 (LIFT-AD) |
| Human efficacy result | None published | Primary endpoint not met, 2024 topline |
| Program status | No disclosed sponsor activity | Sponsor scaled back, pursued strategic alternatives |
Fosgonimeton's Phase 2/3 LIFT-AD trial reported topline results in 2024 indicating it did not meet its primary endpoint, which leaves the shared hepatocyte growth factor and MET hypothesis without a positive human efficacy result behind it.
The preclinical file is genuinely interesting and genuinely thin, and both halves of that sentence hold. The reported findings sit at the mechanism and animal levels only, and the specific published work linking the cognitive effects to the proposed mechanism no longer stands as citable literature. That matters more than the size of the file, because independent replication by unaffiliated laboratories is how preclinical findings earn trust, and here it is sparse.
The mechanistic paper reporting that the procognitive and synaptogenic effects of these angiotensin IV-derived peptides depend on hepatocyte growth factor and c-Met activation was retracted in 2025 after carrying a notice of concern since 2021.
Nothing at this stage is improvised. The contents of an investigational new drug application are set out in regulation and international guidance, and a sponsor either holds them or does not. None of the package below is publicly on record as completed for dihexa.
An investigational new drug package for a compound like this conventionally takes twelve to twenty-four months of dedicated work and costs several million dollars at the low end, and none of it is publicly on record as completed for dihexa.
Regulatory expectations in this field were hardened by decades of late-stage failure, and they are unusually specific as a result. Population selection has become a discipline of its own, since enrolling clinically diagnosed patients without biomarker confirmation historically diluted trials with people who did not carry the pathology being targeted. A growth-factor mechanism sits outside the one accommodation that exists, because biomarker-based accelerated approval has been accepted only for amyloid-lowering agents.
Alzheimer's disease registration trials have conventionally required a cognitive primary such as the ADAS-Cog paired with a functional or global co-primary, twelve to eighteen months of treatment, and two adequate and well-controlled studies.
The dominant safety question here is oncological, and it follows from the proposed mechanism rather than from any observed event. Hepatocyte growth factor signaling through c-Met is one of the better-characterized drivers of cell proliferation, survival, motility and invasion, and an entire class of oncology drugs exists to inhibit it. A therapy that deliberately amplifies that same axis, given daily for years to an elderly population in whom occult malignancy is common, inverts that logic.
Because hepatocyte growth factor signaling through c-Met is an established driver of tumor growth and metastasis, a chronic-use approval would conventionally demand two-year rodent carcinogenicity work plus a complementary model and a long-exposure safety database on the order of fifteen hundred people.
A research use only label is a disclaimer, not a designation. It asserts that the seller is not offering the material for human consumption, which keeps the product outside the drug approval framework rather than clearing any regulatory bar, and it says nothing about whether the substance has been evaluated for safety, purity or effect in people. The dietary supplement route is closed rather than just unused, since an article authorized for investigation as a new drug and made the subject of substantial public clinical investigation is excluded from the definition of a dietary ingredient under United States law.
| Criteria | Research use only material | Approved drug |
|---|---|---|
| Regulatory review | None; the label is a seller's disclaimer | Benefit-risk reviewed for a defined indication and population |
| Manufacturing oversight | No audited standard | Audited conditions, defined strength and formulation |
| Identity and purity | No independent assay, endotoxin or sterility testing | Specification-controlled and released to standard |
| Lawful human marketing | Not permitted | Permitted within approved labeling |
Dihexa is generally not a controlled substance, so what is unlawful is marketing it for human therapeutic use rather than possessing it, and the World Anti-Doping Code separately prohibits substances lacking approval by any governmental regulatory health authority.
The arithmetic of a restart is sobering before probability is even applied. Each stage carries its own multi-year clock and its own budget, and the commonly cited shortcuts do less than expected: fast track, breakthrough therapy and priority review speed up interaction and review without lowering the evidentiary standard. Orphan designation would require a rare-disease indication the compound has no data in.
A restart from investigational new drug enabling work to a regulatory decision would realistically run eight to twelve years and a total spend credibly in the hundreds of millions of dollars, against central nervous system success rates measured in low single-digit percentages.
Educational use only. This article describes what the published scientific and clinical literature reports about Dihexa. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
